Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Enterprise Value (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Enterprise Value data on record, last reported at -$401.6 million in Q3 2025.

  • For Q3 2025, Enterprise Value fell 219.83% year-over-year to -$401.6 million; the TTM value through Sep 2025 reached -$401.6 million, down 219.83%, while the annual FY2024 figure was -$224.3 million, 75.06% down from the prior year.
  • Enterprise Value reached -$401.6 million in Q3 2025 per GLUE's latest filing, down from -$69.4 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$47.0 million in Q2 2023 and bottomed at -$401.6 million in Q3 2025.
  • Average Enterprise Value over 3 years is -$126.8 million, with a median of -$99.8 million recorded in 2024.
  • The widest YoY moves for Enterprise Value: up 36.21% in 2025, down 219.83% in 2025.
  • A 3-year view of Enterprise Value shows it stood at -$128.1 million in 2023, then plummeted by 75.06% to -$224.3 million in 2024, then crashed by 79.09% to -$401.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$401.6 million in Q3 2025, -$69.4 million in Q2 2025, and -$78.5 million in Q1 2025.